Juxtapid ® Homozygous Familial Hypercholesterolemia (HoFH) Treatment


Juxtapid® (Lomitapide) is an FDA approved orphan drug from Aegerion Pharmaceuticals, Inc. (U.S.A) that is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available in patients with homozygous familial hypercholesterolemia (HoFH).
 The safety and effectiveness of Juxtapid have not been established in patients with hypercholesterolemia who do not have HoFH.
The effect of Juxtapid on cardiovascular morbidity and mortality has not been determined.

HoFH is the most severe form of familial hypercholesterolemia. HoFH is caused by genetic defects inherited from both parents that affect the function of the low-density lipoprotein (LDL) receptor, the receptor responsible for removing LDL-C cholesterol (bad cholesterol) from the body. HoFH is characterized by extremely high levels of LDL cholesterol (LDL-C).

Genpharm has an agreement with Aegerion Pharmaceuticals to distribute Juxtapid  in Iran, Iraq, Lebanon and Egypt.

For more information on Juxtapid (Lomitapide) and its availability, please contact us at:

Phone: +971 4  4227010
Email: info@genpharmservices.com

 

For more information about the collaboration between Genpharm and Aegerion Pharmaceuticals, please visit our news section.